title: Perinatal citalopram exposure selectively increases locus ceruleus circuit function in male rats.
abstract: Selective serotonin reuptake inhibitors (SSRIs), such as citalopram (CTM), have been widely prescribed for major depressive disorder, not only for adult populations, but also for children and pregnant mothers. Recent evidence suggests that chronic SSRI exposure in adults increases serotonin (5-HT) levels in the raphe system and decreases norepinephrine (NE) locus ceruleus (LC) neural activity, suggesting a robust opposing interaction between these two monoamines. In contrast, perinatal SSRI exposure induces a long-lasting downregulation of the 5-HT-raphe system, which is opposite to that seen with chronic adult treatment. Therefore, the goal of the present investigation was to test the hypothesis that perinatal CTM exposure (20 mg/kg/d) from postnatal day 1 (PN1) to PN10 leads to hyperexcited NE-LC circuit function in adult rats (>PN90). Our single-neuron LC electrophysiological data demonstrated an increase in spontaneous and stimulus-driven neural activity, including an increase in phasic bursts in CTM-exposed animals. In addition, we demonstrated a corresponding immunoreactive increase in the rate-limiting catalyzing catecholamine enzyme (tyrosine hydroxylase) within the LC and their neocortical target sites compared to saline controls. Moreover, these effects were only evident in male exposed rats, suggesting a sexual dimorphism in neural development after SSRI exposure. Together, these results indicate that administration of SSRIs during a sensitive period of brain development results in long-lasting alterations in NE-LC circuit function in adults and may be useful in understanding the etiology of pervasive developmental disorders such as autism spectrum disorder.
authors.affiliation: Department of Neurobiology and Anatomical Sciences, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA.
authors.forename: Ryan D
authors.initials: RD
authors.lastname: Darling
authors.forename: Loai
authors.initials: L
authors.lastname: Alzghoul
authors.forename: Junlin
authors.initials: J
authors.lastname: Zhang
authors.forename: Nidhi
authors.initials: N
authors.lastname: Khatri
authors.forename: Ian A
authors.initials: IA
authors.lastname: Paul
authors.forename: Kimberly L
authors.initials: KL
authors.lastname: Simpson
authors.forename: Rick C S
authors.initials: RC
authors.lastname: Lin
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000831:Animals, Newborn; D015283:Citalopram / Q000494:pharmacology*; D004299:Dopamine beta-Hydroxylase / Q000378:metabolism; D005260:Female; D008125:Locus Coeruleus / Q000166:cytology / Q000196:embryology / Q000254:growth & development; D008297:Male; D009412:Nerve Fibers / Q000378:metabolism; D009415:Nerve Net / Q000187:drug effects / Q000378:metabolism; D009474:Neurons / Q000187:drug effects*; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000378:metabolism; D010812:Physical Stimulation / Q000009:adverse effects; D011247:Pregnancy; D051381:Rats; D020318:Rats, Long-Evans; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013623:Tail / Q000294:innervation; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D015283:Citalopram; D004299:Dopamine beta-Hydroxylase; D050484:Norepinephrine Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors; D014446:Tyrosine 3-Monooxygenase
references.citation: JAMA. 2005 May 18;293(19):2372-83
references.pmid: 15900008
references.citation: Neuropsychopharmacology. 1988 Dec;1(4):287-95
references.pmid: 2908021
references.citation: Trends Neurosci. 1991 Oct;14(10):468-73
references.pmid: 1722367
references.citation: Int J Dev Neurosci. 2005 Feb;23(1):75-83
references.pmid: 15730889
references.citation: Br J Pharmacol. 1997 Mar;120(5):865-75
references.pmid: 9138693
references.citation: Nat Rev Neurosci. 2003 Dec;4(12):1002-12
references.pmid: 14618156
references.citation: Neuropsychopharmacology. 2006 Jan;31(1):47-57
references.pmid: 16012532
references.citation: Neuropsychopharmacology. 2010 Jul;35(8):1653-63
references.pmid: 20357759
references.citation: J Neurosci Methods. 1980 Dec;3(2):129-49
references.pmid: 6110810
references.citation: Neuroscience. 1995 Mar;65(1):119-60
references.pmid: 7753394
references.citation: Proc Natl Acad Sci U S A. 1975 Feb;72(2):659-63
references.pmid: 235760
references.citation: Br J Pharmacol. 1999 Feb;126(3):568-71
references.pmid: 10188964
references.citation: Brain Res. 1996 Dec 2;742(1-2):89-97
references.pmid: 9117425
references.citation: Clin Pharmacol Ther. 2009 Dec;86(6):672-7
references.pmid: 19890255
references.citation: Brain Res. 1982 Mar 11;235(2):285-301
references.pmid: 6145490
references.citation: J Neurochem. 2005 Jan;92(2):368-74
references.pmid: 15663484
references.citation: Brain Res Brain Res Rev. 2003 Apr;42(1):33-84
references.pmid: 12668290
references.citation: J Pharmacol Exp Ther. 1989 Jul;250(1):37-43
references.pmid: 2526217
references.citation: Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10734-9
references.pmid: 9724773
references.citation: Arch Gen Psychiatry. 2011 Nov;68(11):1104-12
references.pmid: 21727247
references.citation: Trends Pharmacol Sci. 2010 Feb;31(2):60-5
references.pmid: 19963284
references.citation: Brain Res. 1981 Jan 5;204(1):129-46
references.pmid: 7195762
references.citation: J Neurophysiol. 2011 Jan;105(1):69-87
references.pmid: 20980542
references.citation: Proc Natl Acad Sci U S A. 1990 Oct;87(19):7522-6
references.pmid: 1977162
references.citation: Annu Rev Clin Psychol. 2008;4:275-303
references.pmid: 18370618
references.citation: J Neurosci. 1981 Aug;1(8):887-900
references.pmid: 7346593
references.citation: Proc Natl Acad Sci U S A. 1997 May 13;94(10):5308-13
references.pmid: 9144233
references.citation: Biol Psychiatry. 2004 Jun 1;55(11):1103-9
references.pmid: 15158430
references.citation: Neuropsychopharmacology. 2005 Jun;30(6):1039-47
references.pmid: 15688089
references.citation: Int J Dev Neurosci. 2005 Apr-May;23(2-3):171-82
references.pmid: 15749243
references.citation: Neuropsychopharmacology. 2006 Mar;31(3):544-54
references.pmid: 16123744
references.citation: Psychopharmacology (Berl). 2007 Mar;191(1):87-96
references.pmid: 17180618
references.citation: Biol Psychiatry. 2010 Jun 1;67(11):1057-66
references.pmid: 20172503
references.citation: Annu Rev Neurosci. 1999;22:197-217
references.pmid: 10202537
references.citation: Psychother Psychosom. 2007;76(1):5-14
references.pmid: 17170559
references.citation: Science. 1999 Jan 22;283(5401):549-54
references.pmid: 9915705
references.citation: Neuroscience. 2005;130(1):107-17
references.pmid: 15561429
references.citation: J Pediatr. 2003 Apr;142(4):402-8
references.pmid: 12712058
references.citation: J Hum Lact. 2010 May;26(2):187-95
references.pmid: 19652194
references.citation: Am J Obstet Gynecol. 2003 Mar;188(3):812-5
references.pmid: 12634662
references.citation: Int J Neuropsychopharmacol. 2009 Jun;12(5):627-41
references.pmid: 18950545
references.citation: J Neurosci. 2008 Jan 2;28(1):199-207
references.pmid: 18171937
references.citation: Annu Rev Neurosci. 2005;28:403-50
references.pmid: 16022602
references.citation: Ann Neurol. 1999 Mar;45(3):287-95
references.pmid: 10072042
references.citation: Science. 2004 Oct 29;306(5697):879-81
references.pmid: 15514160
references.citation: Brain Res Dev Brain Res. 2004 Jul 19;151(1-2):187-91
references.pmid: 15246704
references.citation: J Comp Neurol. 1978 Mar 1;178(1):1-16
references.pmid: 632368
references.citation: Anat Rec (Hoboken). 2011 Oct;294(10):1726-35
references.pmid: 21905242
references.citation: Anat Rec (Hoboken). 2011 Oct;294(10):1685-97
references.pmid: 21901841
references.citation: Brain Res. 2004 Nov 5;1026(1):56-67
references.pmid: 15476697
references.citation: Anat Rec (Hoboken). 2010 Nov;293(11):1920-32
references.pmid: 20830689
references.citation: Brain Res Bull. 2001 Sep 1;56(1):73-8
references.pmid: 11604252
references.citation: Med Biol. 1977 Feb;55(1):21-40
references.pmid: 15169